middle.news
FDA Endorses Starpharma’s DEP® HER2 Phase 1 Trial Design Ahead of H2 2026 Start
10:12am on Tuesday 21st of April, 2026 AEST
•
Biotechnology
Read Story
FDA Endorses Starpharma’s DEP® HER2 Phase 1 Trial Design Ahead of H2 2026 Start
10:12am on Tuesday 21st of April, 2026 AEST
Key Points
FDA supports DEP® HER2 phase 1 study design and clinical approach
Trial targets patients with advanced HER2-expressing cancers lacking effective therapies
Phase 1 study to begin in Europe, evaluating safety and pharmacokinetics
FDA feedback opens door for potential Fast Track designation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Starpharma (ASX:SPL)
OPEN ARTICLE